Koye Pharmaceuticals Pvt Ltd

Koye Pharmaceuticals Pvt Ltd is a pharmaceutical company focused on developing and manufacturing therapeutic medications that enhance health and wellness, particularly in chronic condition management. Founded in 2013 in Mumbai, India, Koye Pharmaceuticals Pvt Ltd specializes in pharmaceutical product development. The company has executed a total of 8 deals, with its most recent deal occurring on September 2, 2020. Koye Pharmaceuticals raised INR 300 million in a VENTURE DEBT round led by BlackSoil Capital.

The founder, Preetish Toraskar, has been instrumental in shaping the company's strategies and direction. Koye Pharmaceuticals Pvt Ltd specializes in the development and manufacture of pharmaceutical products aimed at enhancing health and wellness. The company's core offerings include a range of therapeutic medications designed to address chronic conditions and improve patient outcomes, particularly in areas such as cardiovascular health, diabetes management, and pain relief. These products are formulated based on rigorous research and clinical trials, ensuring safety and efficacy for the end users, which primarily include hospitals, healthcare providers, and pharmacies.

Koye Pharmaceuticals distributes its products in key geographical markets, notably in North America, Europe, and select regions in Asia, catering to a diverse client base that encompasses both institutional and retail sectors. In the most recent year of 2023, Koye Pharmaceuticals generated revenue of INR 31,818,377. 50 with an EBITDA of INR -6,962,071. 30.

The company operates through a structured B2B model, primarily engaging in direct sales to healthcare institutions and pharmacies, with competitive pricing in the market. Looking ahead, Koye Pharmaceuticals Pvt Ltd plans to launch new therapeutic products targeting specific chronic conditions, although specific release dates have yet to be disclosed. The company aims to expand its market presence in Southeast Asia and Europe by 2025, leveraging the recent VENTURE DEBT funding of INR 300 million raised in September 2020 to support these initiatives. This funding will be critical in facilitating product development and market entry efforts.